Background. Aspirin and other nonsteroidal antiinflammatory
drugs (NSAIDs) have been shown experimentally
to inhibit chemically induced esophageal cancers.
An epidemiologic study of more than 600,000 adults in the
United States followed for 6 years found that aspirin use
was associated with a reduced risk of death from esophageal
cancer